Patents by Inventor Rumen Tsanev

Rumen Tsanev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor of Endogenous Human Interferon-gamma
    Publication number: 20110286966
    Abstract: Modified endogenous human interferon-gamma (hIFN-?), biologically inactive but preserving binding affinity to the hIFN-? receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis.
    Type: Application
    Filed: February 28, 2011
    Publication date: November 24, 2011
    Inventors: Ivan Ivanov, Rumen Tsanev, Genoveva Nacheva, Hans-Guenther Grigoleit, Rolf Gunther
  • Inhibitor of endogenous human interferon-gamma
    Patent number: 7973133
    Abstract: The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ inactivated by physical or chemical methods.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: July 5, 2011
    Inventors: Ivan Ivanov, Rumen Tsanev, Genoveva Nacheva, Hans-Guenther Grigoleit, Rolf Gunther
  • Inhibitor of endogenous human interferon-gamma
    Publication number: 20100158865
    Abstract: The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ, inactivated by physical or chemical methods.
    Type: Application
    Filed: January 20, 2010
    Publication date: June 24, 2010
    Inventors: Ivan Ivanov, Rumen Tsanev, Genoveva Nacheva, Hans-Guenther Grigoleit, Rolf Gunther
  • Inhibitor of Endogenous Human Interferon-Gamma
    Publication number: 20090208452
    Abstract: The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ inactivated by physical or chemical methods.
    Type: Application
    Filed: October 5, 2005
    Publication date: August 20, 2009
    Inventors: Ivan Ivanov, Rumen Tsanev, Genoveva Nacheva, Hans-Guenther Grigoleit, Rolf Gunther